SCHEMBL5743947

SCHEMBL5743947

Cc1ccc(S(=O)(=O)OC2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.57
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
OPRD1 P41143 4/20 0.44
OPRM1 P35372 4/20 0.44
OPRK1 P41145 3/20 0.44
OPRL1 P41146 3/20 0.44
MAOA P21397 1/20 0.43
CACNA2D1 P54289 1/20 0.43
CACNA1B Q00975 1/20 0.43
CACNB1 Q02641 1/20 0.43
CACNA1C Q13936 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL3 Q96JM7 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP3A4 P08684 3/20 0.42
CYP2C19 P33261 1/20 0.42
USP2 O75604 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2264882 0.93 CYP2D6 (0.52) CYP2D6ALDH1A1CYP1A2OPRD1OPRM1
SCHEMBL2265187 0.93 CYP2D6 (0.52) CYP2D6ALDH1A1CYP1A2OPRD1OPRM1
SCHEMBL4673445 0.87 CYP2D6 (0.47) CYP2D6ALDH1A1CYP1A2OPRD1OPRM1
SCHEMBL5746020 0.85 CYP2D6 (0.47) CYP2D6ALDH1A1CYP1A2OPRD1OPRM1
SCHEMBL28966911 0.82 CYP2D6 (0.64) CYP2D6CYP1A2MEN1KMT2ACYP3A4
SCHEMBL5744749 0.82 CYP2D6 (0.50) CYP2D6ALDH1A1CYP1A2OPRD1OPRM1
SCHEMBL5745118 0.82 CYP2D6 (0.50) CYP2D6ALDH1A1CYP1A2OPRD1OPRM1
SCHEMBL5745490 0.81 CYP2D6 (0.50) CYP2D6ALDH1A1OPRD1OPRM1OPRK1
SCHEMBL10039406 0.81 CYP2D6 (0.56) CYP2D6CYP1A2CHRM1HTR2A
SCHEMBL28968116 0.79 CYP2D6 (0.60) CYP2D6ALDH1A1CYP1A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1288198-B1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS KANEKA CORP (JP) 2006-12-20 EP disclosed
US-6992205-B2 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2006-01-31 US disclosed
US-6864372-B2 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2005-03-08 US disclosed
US-6794519-B2 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2004-09-21 US disclosed
US-20030176713-A1 Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base KANEKA CORPORATION (JP) 2003-09-18 US disclosed
US-20030176711-A1 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2003-09-18 US disclosed
US-20030162966-A1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS KANEKA CORPORATION (JP) 2003-08-28 US disclosed
EP-1288198-A1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS KANEKA CORPORATION (JP) 2003-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162966-A1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS TST, STS, SELENOI CYP2D6 675/4885ALDH1A1 646/4885CYP1A2 341/4885
US-20030176711-A1 Process for the production of sulfonic esters TST, STS, SELENOI CYP2D6 675/4885ALDH1A1 646/4885CYP1A2 341/4885
US-20030176713-A1 Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base BRAF, ADH1C, TST CYP2D6 1620/4885ALDH1A1 498/4885CYP1A2 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.